articleTop 1% cited

Phase 3 trial of everolimus for metastatic renal cell carcinoma

Cancer · 2010 · Vol. 116(18) · pp. 4256–4265

Robert J. Motzer✉(Memorial Sloan Kettering Cancer Center)Bernard Escudier(Institut Gustave Roussy)Stéphane Oudard(Translational Research in Oncology)Thomas E. Hutson(Texas Oncology)Camillo Porta(Istituti di Ricovero e Cura a Carattere Scientifico)Sergio Bracarda(Ospedale San Donato)Viktor Grünwald(Medizinische Hochschule Hannover)John A. Thompson(Seattle Cancer Care Alliance)Robert A. Figlin(City Of Hope National Medical Center)Norbert Hollaender(Novartis (Switzerland))Andrea Kay(Novartis (United States))Alain Ravaud(Hôpital Saint-André)for the RECORD‐1 Study Group

View via DOI Publisher page

Abstract

These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.

Renal cell carcinoma treatment Renal and related cancers Cancer Genomics and DiagnosticsEverolimusMedicinePlaceboHazard ratioInternal medicineInterim analysisRenal cell carcinomaOncologyProportional hazards modelGastroenterology

MeSH terms

EverolimusAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Renal CellDouble-Blind MethodHumansKidney NeoplasmsMiddle AgedNeoplasm MetastasisPlacebosPrognosisRetreatmentSirolimus

Citations

1,140

FWCI

91.88

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Treatment of renal cell carcinoma: Current status and future directions